Novartis ag - Articles - Page 35

Bio-Europe Spring 2020

Closing panel offers COVID-19 lessons to learn from China

March 27, 2020

Biopharma industry leaders in China who were the first to experience the chaos of the COVID-19 pandemic shared their thoughts during a closing plenary session of the virtual Bio-Europe Spring 2020 meeting.

Competition aplenty as Novartis’ Isturisa is FDA-approved to treat Cushing’s disease

March 9, 2020

By Lee Landenberger

With the FDA approval of Novartis AG’s Isturisa (osilodrostat), an oral treatment for adults with Cushing’s disease, Recordati SpA, of Milan, is planning its U.S. market launch for the second or third quarter of this year. Recordati, which acquired Isturisa’s worldwide rights from Novartis in October for $390 million, expects sales to peak at $100 million annually.

Newco news

The stars shine on Orionis as it embarks on a deal with Novartis

March 5, 2020

By Lee Landenberger

Orionis Biosciences Inc. has begun a four-year collaboration with Novartis AG to discover and design small-molecule therapeutics such as protein degraders that target several therapeutic areas, including cancer. The agreement’s terms include research funding a convertible note investment, royalties and potential clinical milestones.

Biocom Global Life Sciences Partnering Conference

Pharmas share their needs, wants and offer some advice

March 2, 2020

By Brian Orelli

SAN DIEGO – At the Biocom 10th Annual Global Life Sciences Partnering Conference, panels of pharma executives highlighted what they're looking for to supplement their pipelines and offered advice that ran the gamut from company formation to the courting process to strategies for partnering pipeline drugs and platforms.

BioAsia 2020

India could be instrumental in lowering price of CAR T-cell therapy

Feb. 25, 2020

By T.V. Padma

HYDERABAD, India – India could play a key role in driving down the exorbitant cost of emerging cell and gene therapies, with a combination of comparatively cheap labor and efficient manufacturing, international experts said during the annual BioAsia conference.

BioAsia 2020

India could be instrumental in lowering price of CAR T-cell therapy

Feb. 19, 2020

By T.V. Padma

HYDERABAD, India – India could play a key role in driving down the exorbitant cost of emerging cell and gene therapies, with a combination of comparatively cheap labor and efficient manufacturing, international experts said during the annual BioAsia conference.

Metabolic: Inclisiran, Rybelsus

Novartis’ high ‘steaks’ with inclisiran in FH; optimism for Rybelsus in diabetes

Feb. 10, 2020

By Randy Osborne

The less-frequent dosing regimen of Basel, Switzerland-based Novartis AG’s cholesterol therapy, inclisiran, under development in the hands of subsidiary The Medicines Co., positions the small interfering RNA (siRNA) drug to take on marketed proprotein convertase subtilisin/kexin type 9 (PCSK9)-targeting antibodies as well as statins in the busy therapeutic space. Statins are the gold standard now, but about 80% of patients don’t reach their lipid goals.

Improving average

Biopharma sector scores the approval of 48 new medicines in 2019

Dec. 31, 2019

By Peter Winter

After a flurry of activity in December, when the FDA approved seven new molecular entities (NMEs), the total of novel drugs that were given the green light this year reached 48, a number that ranks third behind the record 59 new medicines the agency approved last year and 53 in 1996.

Pear Therapeutics, Novartis look to tackle depressive symptoms in MS patients

Dec. 17, 2019

By Liz Hollis

Digital therapeutics have made great strides in recent years, with Pear Therapeutics Inc. playing a key role. Now, the company has reported the dosing of the first patient in part two of a study assessing Pear-006 to address depressive symptoms in multiple sclerosis (MS).

Pear Therapeutics, Novartis look to tackle depressive symptoms in MS patients

Dec. 17, 2019

By Liz Hollis

Digital therapeutics have made great strides in recent years, with Pear Therapeutics Inc. playing a key role. Now, the company has reported the dosing of the first patient in part two of a study assessing Pear-006 – which Pear Therapeutics is developing in collaboration with Basel, Switzerland-based Novartis AG – to address depressive symptoms in multiple sclerosis (MS).